The International Society for CNS Clinical Trials and Methodology (ISCTM) is an independent multi-disciplinary organization devoted to promoting advances in, and dissemination of, clinical research methods related to development and use of CNS therapeutics. The ISCTM accomplishes this by bringing together international stakeholders representing academia, industry, government, payers, policymakers, and the public to address strategic clinical, regulatory, methodological and policy challenges in clinical research.

This society specifically deals with the strategic aspects of clinical trial design, other methodological issues and regulatory issues that confound CNS drug development.

In particular, existing forums do not adequately address gaps/disconnects among objectives/indications, regulatory demands/requirements and clinical feasibility in the CNS area.

In contrast, the fields of oncology, immunology, and cardiology have developed extensive interactions among academics, regulators, and industry scientists, and this process has significantly improved clinical research in these disciplines.